---
layout: post
title: 2010 New Drug Approvals - Pt. XV - Lurasidone (Latuda)
date: '2010-11-09T12:43:00.012Z'
author: Patricia
tags:
- Small Molecule Drugs
- 2010 New Drugs
modified_time: '2010-12-24T09:05:38.639Z'
thumbnail: http://2.bp.blogspot.com/_SlPG9DIz_AA/TRMgB8YBqVI/AAAAAAAAA98/xNoBR73MMCk/s72-c/timthumb.php.jpeg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6661264174546873870
blogger_orig_url: http://chembl.blogspot.com/2010/11/2010-new-drug-approvals-pt-xv.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://2.bp.blogspot.com/_SlPG9DIz_AA/TRMgB8YBqVI/AAAAAAAAA98/xNoBR73MMCk/s1600/timthumb.php.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/_SlPG9DIz_AA/TRMgB8YBqVI/AAAAAAAAA98/xNoBR73MMCk/s1600/timthumb.php.jpeg" /></a></div><div class="separator" style="clear: both; text-align: center;"><br />
</div><div class="separator" style="clear: both; text-align: center;"><a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,1,0,1" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5506360071710601538" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,1,0,1" style="cursor: pointer; display: block; height: 47px; margin: 0px auto 10px; text-align: center; width: 400px;" /></a></div><center style="text-align: auto;"><br />
</center><center>ATC code (partial): N05AE</center><br />
<br />
On October 28th 2010, the FDA approved Lurasidone (Tradename:Latuda) (Lurasidone is also known by the research code SM-13,496). Lurasidone is an <a href="http://en.wikipedia.org/wiki/Atypical_antipsychotic">atypical antipsychotic</a> agent indicated for the treatment schizophrenia.<br />
<br />
Lurasidone displays broad polypharmacology against a wide range of rhodopsin-like aminergic GPCRs, acting as an antagonist with high affinity at dopamine D2 receptors (Uniprot: <a href="http://www.uniprot.org/uniprot/P14416">P14416</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/72">72</a>) (Ki of 1 nM), serotonin 5-HT2A (Uniprot: <a href="http://www.uniprot.org/uniprot/P28223">P28223</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/107">107</a>) (Ki of 0.47 nM) and 5-HT7 receptors (Uniprot: <a href="http://www.uniprot.org/uniprot/P34969">P34969</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/10209">10209</a>) (Ki of 0.49 nM), and with moderate affinity at alpha-2C adrenergic receptors (Uniprot: <a href="http://www.uniprot.org/uniprot/P18825">P18825</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/218">218</a>) (Ki of 10.8 nM) and at alpha-2A adrenergic receptors (Uniprot: <a href="http://www.uniprot.org/uniprot/P08913">P08913</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/52">52</a>) (Ki of 40.7 nM). Lurasidone acts also as a partial agonist at serotonin 5-HT1A receptors (Uniprot: <a href="http://www.uniprot.org/uniprot/P08908">P08908</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/51">51</a>) (Ki of 6.4 nM) and exhibits little or no affinity for histamine H1 (Uniprot: <a href="http://www.uniprot.org/uniprot/P35367">P35367</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/127">127</a>) and muscarinic M1 receptors (Uniprot: <a href="http://www.uniprot.org/uniprot/P11229">P11229</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/61">61</a>) (IC50 &gt; 1000 nM and IC50 &gt; 1000 nM, respectively). The efficacy of Luasidone is thought to be primarily related to the D2 and 5HT2A antagonism. All atypical antipsychotics display this complex polypharmacology.<br />
<br />
Lurasidone is a synthetic small-molecule drug (Molecular Weight of 492.7 g/mol for Lurasidone itself and 529.14 g.mol-1 for the dosed HCl salt), is fully Rule-of-Five compliant, lipophilic and very slightly soluble in water.<br />
<br />
Lurasidone has low systemic bioavailability (9-19%), and a high volume of distribution of 6173L, and displays high plasma protein binding (ppb) of ~99%. The half life is 18 hours, and steady-state plasma levels are reached 7 days after starting regular dosing. Lurasidone is predominantly metabolized by CYP3A4 into four major metabolites (two active metabolites and two 'inactive') - metabolites include hydroxylation of the nornbornane ring, N-dealkylation and S-oxidation. The apparent clearance is 3902mL/min, with the bulk of the drug being excreted in the feces.  Dosage is oral, with a recommended starting dosage is 40 mg once daily (equivalent to 81umol), with a recommended maximum dosage of 80 mg daily.<br />
<br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://3.bp.blogspot.com/_GrFxGiayAGE/TM7Oy05vcqI/AAAAAAAAAfY/y902fnlPDoQ/s1600/Lurasidone.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" style="margin-left: 1em; margin-right: 1em;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5534588364674527906" src="http://3.bp.blogspot.com/_GrFxGiayAGE/TM7Oy05vcqI/AAAAAAAAAfY/y902fnlPDoQ/s320/Lurasidone.png" style="display: block; height: 130px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: center; width: 320px;" /></a></div><br />
Lurasidone is a chiral benzoisothiazol derivative - the benzoisothiazol is the fused five-six dual ring structure on the right of the figure above. Its structure (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione contains an imide heterocyclic and a piperazine functional group. The central piperazine nitrogen is basic. The chemical structure, properties and pharmacology are similar to <a href="http://en.wikipedia.org/wiki/Ziprasidone">Ziprasidone</a> (Trademark:Geodon). <br />
<br />
<pre>NAME="Lurasidone"
TRADEMARK_NAME="Latuda"
ATC_code= NA
SMILES="O=C1C2[C@@H]3CC[C@@H](C3)C2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc7ccccc67"
InChI="InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24?,25?/m0/s1"
ChemDraw=<a href="http://www.ebi.ac.uk/chembl/downloads/Lurasidone.cdx">Lurasidone.cdx</a></pre><br />
The full prescribing information can be found <a href="http://www.latuda.com/LatudaPrescribingInformation.pdf">here</a>.<br />
<br />
Lurasidone has a boxed warning (colloquially known as a 'black box').<br />
<br />
The license holder is <a href="http://www.sunovion.com/">Sunovion Pharmaceuticals Inc.</a><span class="Apple-style-span" style="font-family: inherit;"> and the product website is </span><a href="http://www.latuda.com/">www.latuda.com</a>